The Commission on Excellence and Innovation in Health (CEIH)’s Post

ANDHealth welcomes the Albanese Government’s commitment to develop a unified National Health and Medical Research Strategy to guide investment into health and medical research. The announcement also included a reaffirmation of the importance of the Medical Research Future Fund (MRFF) and its existing streams, by way of a $1.4 billion commitment to the Medical Research Future Fund, including: 🔹 A new 10-Year Low Survival Cancers Mission 🔹 A new 10-Year Reducing Health Inequities Mission 🔹 Continuing existing streams of life-changing MRFF funding ANDHealth CEO Bronwyn Le Grice said: “There is tremendous potential for Australia to rapidly rise through the entrepreneurship ranks if it invests smartly and builds upon Australia’s deep roots in traditional health and medical research capability.” “We warmly welcome this announcement of a unified national strategy, which is desperately needed to deliver better-aligned health and medical research outcomes, and we look forward to working with the government to develop a cohesive strategy.” Read more: https://loom.ly/zM44tzw

Clinical Research 2024 Conference which is scheduled during August 08-09, 2024 at London, UK is just around the corner. This year, we're bringing together leading experts, researchers, and practitioners from around the world to discuss the latest advancements and trends in clinical research. #ClinicalResearch2024 #medicalinnovation #healthcareleaders #networking #healthcareprofessionals #Workshops #handsonlearning #medicaleducation

Dr Martin Johnson, Medical Director at FutureMeds UK, delivered a speech at a roundtable in April, encouraging industry leaders to      🎯 Explore the need for a professional body representing site management and clinical research organisations in the UK.     Hosted by The RSA Group and chaired by Lord James O'Shaughnessy, the roundtable concluded with      + unanimous support for establishing a professional body, and      + a shared vision of how it could benefit the sector as a whole and, more importantly, the patients.      "𝙒𝙝𝙞𝙡𝙚 𝙩𝙝𝙚 𝙩𝙖𝙨𝙠 𝙞𝙨 𝙙𝙖𝙪𝙣𝙩𝙞𝙣𝙜, 𝙩𝙝𝙚 𝙥𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 𝙧𝙚𝙬𝙖𝙧𝙙𝙨 𝙞𝙣 𝙩𝙚𝙧𝙢𝙨 𝙤𝙛 𝙚𝙣𝙝𝙖𝙣𝙘𝙚𝙙 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙚𝙛𝙛𝙞𝙘𝙖𝙘𝙮, 𝙞𝙢𝙥𝙧𝙤𝙫𝙚𝙙 𝙥𝙖𝙩𝙞𝙚𝙣𝙩 𝙤𝙪𝙩𝙘𝙤𝙢𝙚𝙨, 𝙖𝙣𝙙 𝙖 𝙢𝙤𝙧𝙚 𝙧𝙤𝙗𝙪𝙨𝙩 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙚𝙘𝙤𝙨𝙮𝙨𝙩𝙚𝙢 𝙞𝙣 𝙩𝙝𝙚 𝙐𝙆 𝙖𝙧𝙚 𝙘𝙤𝙢𝙥𝙚𝙡𝙡𝙞𝙣𝙜." Added Dr Martin Johnson     "𝙏𝙝𝙞𝙨 𝙢𝙚𝙚𝙩𝙞𝙣𝙜, 𝙩𝙝𝙚𝙧𝙚𝙛𝙤𝙧𝙚, 𝙬𝙖𝙨 𝙣𝙤𝙩 𝙟𝙪𝙨𝙩 𝙖 𝙘𝙖𝙡𝙡 𝙩𝙤 𝙖𝙘𝙩𝙞𝙤𝙣 — 𝙞𝙩 𝙬𝙖𝙨 𝙖 𝙨𝙩𝙚𝙥 𝙩𝙤𝙬𝙖𝙧𝙙 𝙧𝙚𝙖𝙡𝙞𝙨𝙞𝙣𝙜 𝙖 𝙫𝙞𝙨𝙞𝙤𝙣 𝙩𝙝𝙖𝙩 𝙘𝙤𝙪𝙡𝙙 𝙧𝙚𝙙𝙚𝙛𝙞𝙣𝙚 𝙩𝙝𝙚 𝙛𝙪𝙩𝙪𝙧𝙚 𝙤𝙛 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙞𝙣 𝙩𝙝𝙚 𝙐𝙆."     We would like to express our gratitude to everyone who joined and contributed and to Caroline Hunt for bringing together several industry leaders to discuss this key topic.      Learn more: https://lnkd.in/e9-N7qxb    #ClinicalTrials #ClinicalResearch 

🔬✨ UEG Congress in Vienna: Innovations & Global Collaboration ✨🔬 The UEG Congress in Vienna brings together experts from around the world to discuss the latest advancements in medicine. It’s inspiring to see professionals from various countries unite to share knowledge and drive innovation. 🌍 Innovations in Medicine: This year, groundbreaking discoveries and technologies are showcased, from personalized therapies to AI in diagnostics, all aimed at improving patient care. 🤝 Global Networking: The congress fosters collaboration among leading researchers and healthcare professionals, highlighting how international efforts can tackle current health challenges. The UEG Congress is a testament to the power of global cooperation in advancing healthcare. #UEGCongress #MedicalInnovation #GlobalCollaboration #Healthcare

Some observations from the Prix Galien, celebrating great work in Life Sciences and Healthcare. These thoughts are from the day's third panel on Innovation in R&D: The Birth of Breakthroughs Key takeaways: Combination Driving Success: The collaboration between humans and AI, along with the integration of therapeutic and behavioural interventions, is revolutionising R&D. Predictability and Diagnostics: Leveraging individual-level predictability offers significant advantages, but the benefits hinge on the availability of low-cost diagnostics. Challenges in Insured Markets: While beneficial in systems like the NHS, insured markets face challenges where regulators must prevent individual data from creating uninsurable population groups. European Innovation Landscape: Europe is a hub for science and innovation, yet it lags behind the US in securing the necessary funding to bring innovations to market. Ecosystem Collaboration: Effective R&D increasingly relies on ecosystems, with nationalist procurement strategies proving counterproductive. Paradox of Innovation: Despite struggles in health systems globally, we are witnessing groundbreaking innovations such as CAR-T therapies, affordable genome sequencing, and new treatments for neurodegeneration. Healthy Population, Healthy Economy: Governments are recognising that a healthy population drives a healthy economy, with prevention, personal responsibility, multi-professional healthcare providers, and early intervention being key factors. Public Health vs. the National Sickness Service: In the UK, there is a need to shift focus from treatment in large hospitals to prevention and quality of life, aligning public health efforts with a proactive approach. Our mission is to help innovation deliver on its potential to help patients. If you share our vision, let's connect! #LifeSciences #Healthcare #PatientPathways #PatientCentric #Consulting #PrixGalien #Innovation #NHS #IntegratedCare #Technology #Digital #R&D

Dr Pramod Kashid, CEO, Expecto Health Science will be speaking at the Singapore Clinical Research Institute (SCRI) Clinical Trials Symposium 2024 next week. Join him for an insightful session where he will delve into how digital technologies and patient-centric approaches are reshaping the clinical trial experience. A renowned industry expert, his presentation will focus on how decentralized clinical trials (DCTs) are changing the game for patient participation and are revolutionizing the landscape of medical research. #ClinicalTrials #DecentralizedTrials #ClinicalResearch #APAC #healthcare #SCRIClinicalTrialsSymposium2024 #TransformingTomorrowsHealth #PatientCentric #Singapore

In most #clinicaltrials, the cost of research interventions is typically covered by the sponsor or through a grant from a governmental or private organization. When research activities lack this financial support, researchers must consider alternative models.  However, there are significant concerns with expecting participants to bear the financial burden of research participation, even when the study closely resembles standard medical care. At WCG, our general position is research participants should not have to pay for their research intervention, including participant’s direct costs in different types of studies, from clinical trials of high-risk FDA-regulated products to unregulated novel concepts.  In our latest insight, we dive into several layers of issues to address when discussing studies that require participants to pay to participate. Read now at https://lnkd.in/ezR-NnzB #clinicalresearch #WCG #IRBreview 

The MENA region holds great potential for medical advancements, yet it remains underrepresented in global clinical research. Increasing the number of clinical trials is crucial for ensuring effective and safe treatments for diverse populations. We are committed to addressing this gap through regulatory harmonization, infrastructure development, capacity building, public awareness, and collaborative networks. By focusing on these key areas, we aim to create a more inclusive global health research landscape. Together, we can unlock the region's potential for groundbreaking medical innovations. #ClinicalTrials #MENARegion #HealthResearch #GlobalHealth

Happy New Year from MTRG! We want to take a moment to reflect on our accomplishments in the year 2023. 🌐 Global Presence at ISPOR Events: We had the privilege of participating in two major ISPOR conferences - ISPOR US and ISPOR Europe. In these events we presented research on #digitalhealth and #genomicsequencing value assessment, sustainable #healthfinancing in the ASEAN6 region, the (potential) impact of secondary prevention of CVD in Europe and #HTA of first-in-class drugs. 📚 Peer-Reviewed Publications: Our team published seven peer-reviewed articles in the field of health economics and policy, covering a range of topics. 1️⃣ "How can health technology assessment be improved to optimize access to medicines? Results from a Delphi study in Europe." (Published in Eur J Health Econ, 2023). 2️⃣ "Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions." (Published in Medical Decision Making, 2023). 3️⃣ "A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United Kingdom." (Published in Social Science & Medicine, 2023). 4️⃣ "A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach." (Published in Value in Health, 2023). 5️⃣ "The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective." (Published in Hellenic Journal of Cardiology, 2023). 6️⃣ "Road traffic mortality and economic uncertainty: Evidence from the United States." (Published in Social Science & Medicine, 2023). 7️⃣ "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries." (Published in Social Science & Medicine, 2023). We are excited to continue sharing more of our research with you in 2024! #healthpolicy #hta #healthtechnology #digitalhealth #research If you are interested in learning more about our research, please take a look at our website below. https://lnkd.in/g7Pg4UHr

🚨🚨🚨 Last chance to register! Join us and top industry experts from FDA, Howard University, Public Health Innovators, and Digital Medicine Society (DiMe) for our Journal Club tomorrow at 11 a.m. ET. This discussion will focus on “Defining the Dimensions of Diversity to Promote Inclusion in the Digital Era of Healthcare”. 💊 As conventional medicine shifts toward digital medicine, we have the opportunity to intentionally develop and deploy DHTs with an inclusion focus. The first step is ensuring that the multiple dimensions of diversity are captured; we propose a lexicon that encompasses elements critical for implementing an inclusive approach to advance healthcare quality and health services research in the digital era. 🤝 Join these experts as they discuss why it is important that the intersectionality of the diversity dimensions is represented in healthcare and clinical research. The lexicon for the dimensions of diversity can inform strategies and resources for more inclusive digital product development and deployment. 🔗 Register now to be part of this insightful conversation: https://bit.ly/3TAoO3C